February 12, 2019
1 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Phase 2 data show IOP reduction for 1 year with iDose
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, L. Jay Katz, MD, chief medical officer at Glaukos, discusses phase 2 data for the company’s iDose device, which releases a continuous dose of travoprost.